| |||||||||||||||
|
Home
|
Jan. 28 - NCCN Updates Breast Cancer Guidelines The National Comprehensive Cancer Network (NCCN) is proud to announce several new updates to the NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer. These changes highlight leading developments in the treatment of breast cancer and represent the recognized standard for clinical care in oncology in both the community and the academic practice settings. A new section focusing on the treatment of patients with inflammatory breast cancer (IBC) has been added. IBC is a rare, aggressive form of breast cancer estimated to account for 1% to 6% of breast cancer cases in the United States. IBC is characterized by redness and swelling of the skin of the breast due to blockage of lymph vessels by cancer cells. Recommendations from the NCCN Guideline Panel for treatment of IBC (without evidence of metastases) involve a combined modality approach including preoperative chemotherapy with an anthracycline with or without a taxane followed by total mastectomy and radiation therapy for patients responding to preoperative chemotherapy. In the latest version of the NCCN Guidelines, the option of using a gene-based assay of tumor tissue (Oncotype DX®, Genomic Health) to help guide chemotherapy treatment decisions is now included within the systemic adjuvant treatment decision pathway for patients with hormone receptor-positive, HER2-negative tumors that are 0.6 to 1.0 cm and moderately/poorly differentiated or with unfavorable features, or greater than 1 cm. Bevacizumab (Avastin®, Genentech) continues to be a recommended therapy in combination with paclitaxel for the treatment of recurrent or metastatic breast cancer. The NCCN Breast Cancer Guideline V.2.2008 now includes new sections covering principles of breast reconstruction following mastectomy and principles of radiation therapy. Source: National Comprehensive Cancer Network
|
|
|
3801 Schuylkill Rd • Spring City, PA 19475 Publishers of Radiology Today All rights reserved. |